Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia

What Was Tested

The paper reports a study of Glucagon and GIP (Gastric Inhibitory Polypeptide) in the context of fatty liver & elevated liver enzymes, published as a controlled clinical trial.

The researchers evaluated whether patients with histologically verified nonalcoholic fatty liver disease (NAFLD) have an impaired incretin effect and hyperglucagonaemia.

Who Took Part

The abstract describes 10 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

All participants underwent a 50-g oral glucose tolerance test (OGTT) and an isoglycaemic intravenous glucose infusion (IIGI).

How the Study Was Run

The researchers determined the incretin effect by relating the beta cell secretory responses during the OGTT and IIGI.

Data are presented as medians (interquartile range), and the groups were compared by using the Kruskal-Wallis test.

What Was Measured

PubMed files the paper under topics including Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Fasting, Gastric Inhibitory Polypeptide, Glucagon and Glucagon-Like Peptide 1.

Author keywords: glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, incretin effect, nonalcoholic fatty liver disease and type 2 diabetes.

What This Means in Plain Language

This is a controlled clinical trial of Glucagon and GIP (Gastric Inhibitory Polypeptide) in 10 patients in people with fatty liver & elevated liver enzymes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Journal of internal medicine), a journal based in England.

More context: the Glucagon compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, Fatty liver & elevated liver enzymes research.